Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et pathologiques
Guyatt, G.H., Oxman, A.D., Kunz, R., Atkins, D., Brozek, J., Vist, G., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64 (2011), 395–400.
Taylor, D.W., Barnett, H.J., Haynes, R.B., Ferguson, G.G., Sackett, D.L., Thorpe, K.E., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 353 (1999), 2179–2184.
King, A., Bath, P.M., Markus, H.S., Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 42 (2011), 650–655.
Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 355 (2000), 346–351.
Hiatt, W.R., Fowkes, F.G., Heizer, G., Berger, J.S., Baumgartner, I., Held, P., et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 376 (2017), 32–40.
Decousus, H., Prandoni, P., Mismetti, P., Bauersachs, R.M., Boda, Z., Brenner, B., et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363 (2010), 1222–1232.
Markus, H.S., Levi, C., King, A., Madigan, J., Norris, J., Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results. JAMA Neurol 76 (2019), 657–664.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996), 1329–1339.
Markus, H.S., Droste, D.W., Kaps, M., Larrue, V., Lees, K.R., Siebler, M., et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111 (2005), 2233–2240.
Belch, J.J., Dormandy, J., Biasi, G.M., Cairols, M., Diehm, C., Eikelboom, B., et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 52 (2010), 825–833.
Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 (2013), 11–19.
Bhatt, D.L., Fox, K.A., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
Anand, S.S., Bosch, J., Eikelboom, J.W., Connolly, S.J., Diaz, R., Widimsky, P., et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391 (2018), 219–229.
Mantese, V.A., Timaran, C.H., Chiu, D., Begg, R.J., Brott, T.G., The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): stenting versus carotid endarterectomy for carotid disease. Stroke 41 (2010), S31–S34.
Halkes, P.H., van Gijn, J., Kappelle, L.J., Koudstaal, P.J., Algra, A., Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006), 1665–1673.
Diener, H.C., Cunha, L., Forbes, C., Sivenius, J., Smets, P., Lowenthal, A., European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996), 1–13.
Kennedy, J., Hill, M.D., Ryckborst, K.J., Eliasziw, M., Demchuk, A.M., Buchan, A.M., Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6 (2007), 961–969.
Tepe, G., Bantleon, R., Brechtel, K., Schmehl, J., Zeller, T., Claussen, C.D., et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy–the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 22 (2012), 1998–2006.
Devereaux, P.J., Mrkobrada, M., Sessler, D.I., Leslie, K., Alonso-Coello, P., Kurz, A., et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370 (2014), 1494–1503.
Johnston, S.C., Easton, J.D., Farrant, M., Barsan, W., Conwit, R.A., Elm, J.J., et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 379 (2018), 215–225.
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
Diener, H.C., Sacco, R.L., Yusuf, S., Cotton, D., Ounpuu, S., Lawton, W.A., et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7 (2008), 875–884.
Cosmi, B., Filippini, M., Tonti, D., Avruscio, G., Ghirarduzzi, A., Bucherini, E., et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 10 (2012), 1026–1035.
Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 163 (2003), 1657–1663.
Beyer-Westendorf, J., Schellong, S.M., Gerlach, H., Rabe, E., Weitz, J.I., Jersemann, K., et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 4 (2017), e105–e113.
Johnston, S.C., Amarenco, P., Denison, H., Evans, S.R., Himmelmann, A., James, S., et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med 383 (2020), 207–217.
Morrow, D.A., Braunwald, E., Bonaca, M.P., Ameriso, S.F., Dalby, A.J., Fish, M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366 (2012), 1404–1413.
Bonaca, M.P., Bauersachs, R.M., Anand, S.S., Debus, E.S., Nehler, M.R., Patel, M.R., et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 382 (2020), 1994–2004.
Anand, S., Yusuf, S., Xie, C., Pogue, J., Eikelboom, J., Budaj, A., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007), 217–227.
Guillemin, F., de Wit, M., Fautrel, B., Grimm, S., Joore, M., Boonen, A., Steps in implementing a health economic evaluation. RMD Open, 6, 2020.
Brouwers, M.C., Kerkvliet, K., Spithoff, K., The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 352, 2016, i1152.
Behrendt, C.A., Kreutzburg, T., Nordanstig, J., Twine, C.P., Marschall, U., Kakkos, S., et al. The OAC3-PAD risk score predicts major bleeding events at one year after hospitalisation for peripheral artery disease. Eur J Vasc Endovasc Surg 63 (2022), 503–510.
Zlatanovic, P., Wong, K.H.F., Kakkos, S.K., Twine, C.P., A Systematic Review and Meta-Analysis on the Impact of High On-Treatment Platelet Reactivity on Clinical Outcomes for Patients Taking ADP Receptor Inhibitors Following Lower Limb Arterial Endovascular Intervention. Eur J Vasc Endovasc Surg 63 (2022), 91–101.
Wong, K.H.F., Zlatanovic, P., Bosanquet, D.C., Saratzis, A., Kakkos, S., Aboyans, V., et al. Antithrombotic therapy for aortic and peripheral artery aneurysms: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 64 (2022), 544–556.
Mohamed, I., Kamarizan, M.F.A., Da Silva, A., Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev, 7, 2021, Cd002786.
Naylor, R., Rantner, B., Ancetti, S., de Borst, G.J., De Carlo, M., Halliday, A., et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg 65 (2023), 7–111.
Aboyans, V., Bauersachs, R., Mazzolai, L., Brodmann, M., Palomares, J.F.R., Debus, S., et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 42 (2021), 4013–4024.
Aboyans, V., Ricco, J.B., Bartelink, M.E.L., Björck, M., Brodmann, M., Cohnert, T., et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55 (2018), 305–368.
Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., Drachman, D.E., et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 69 (2017), e71–e126.
Schmidli, J., Widmer, M.K., Basile, C., de Donato, G., Gallieni, M., Gibbons, C.P., et al. Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55 (2018), 757–818.
Lok, C.E., Huber, T.S., Lee, T., Shenoy, S., Yevzlin, A.S., Abreo, K., et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 75 (2020), S1–S164.
Wanhainen, A., Verzini, F., Van Herzeele, I., Allaire, E., Bown, M., Cohnert, T., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg 57 (2019), 8–93.
Bjorck, M., Koelemay, M., Acosta, S., Bastos Goncalves, F., Kolbel, T., Kolkman, J.J., et al. Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 53 (2017), 460–510.
Debette, S., Mazighi, M., Bijlenga, P., Pezzini, A., Koga, M., Bersano, A., et al. ESO guideline for the management of extracranial and intracranial artery dissection. Eur Stroke J 6 (2021), XXXIX–LXXXVIII.
Black, S.A., Alvi, A., Baker, S.J., Beckett, D., Breen, K., Burfitt, N.J., et al. Management of acute and chronic iliofemoral venous outflow obstruction: a multidisciplinary team consensus. Int Angiol 39 (2020), 3–16.
Stevens, S.M., Woller, S.C., Kreuziger, L.B., Bounameaux, H., Doerschug, K., Geersing, G.J., et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 160 (2021), e545–e608.
McCormack, T., Harrisingh, M.C., Horner, D., Bewley, S., Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ, 369, 2020, m1565.
De Maeseneer, M.G., Kakkos, S.K., Aherne, T., Baekgaard, N., Black, S., Blomgren, L., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg 63 (2022), 184–267.
Kakkos, S.K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S.A., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg 61 (2021), 9–82.
Higgins, J.P., Lasserson, T., Chandler, J., Tovey, D., Churchill, R., Methodological Expectations of Cochrane Intervention. 2016, Cochrane, London.
Ambler, G.K., Waldron, C.A., Contractor, U.B., Hinchliffe, R.J., Twine, C.P., Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg 107 (2020), 20–32.
Weissler, E.H., Jones, W.S., Desormais, I., Debus, S., Mazzolai, L., Espinola-Klein, C., et al. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis 315 (2020), 10–17.
Mehran, R., Rao, S.V., Bhatt, D.L., Gibson, C.M., Caixeta, A., Eikelboom, J., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
Lapébie, F.X., Aboyans, V., Lacroix, P., Constans, J., Boulon, C., Messas, E., et al. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. Eur J Vasc Endovasc Surg 62 (2021), 439–449.
Søgaard, M., Nielsen, P.B., Skjøth, F., Larsen, T.B., Eldrup, N., Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. Eur J Vasc Endovasc Surg 63 (2022), 285–294.
Montalto, C., Munafo, A.R., Arzuffi, L., Casula, M., Mandurino-Mirizzi, A., Costa, F., et al. Validation of the ARC-HBR criteria in 68,874 patients undergoing PCI: A systematic review and meta-analysis. Hellenic J Cardiol 66 (2022), 59–66.
Costa, F., van Klaveren, D., James, S., Heg, D., Raber, L., Feres, F., et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389 (2017), 1025–1034.
Khan, S.U., Lone, A.N., Asad, Z.U.A., Rahman, H., Khan, M.S., Saleem, M.A., et al. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease. Cardiovasc Revasc Med 20 (2019), 1125–1133.
Moayyedi, P., Eikelboom, J.W., Bosch, J., Connolly, S.J., Dyal, L., Shestakovska, O., et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology 157 (2019), 403–412.e5.
Ducrocq, G., Wallace, J.S., Baron, G., Ravaud, P., Alberts, M.J., Wilson, P.W., et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 31 (2010), 1257–1265.
Lv, M., Zheng, X., Wu, T., Chen, W., Jiang, S., Zhang, H., et al. A New Score for Predicting Acute Gastrointestinal Bleeding in Patients Administered Oral Antiplatelet Drugs. Front Pharmacol, 11, 2020, 571605.
Petersen, J., Møller Hansen, J., de Muckadell, O.B.S., Dall, M., Hallas, J., A model to predict the risk of aspirin/non-steroidal anti-inflammatory drugs-related upper gastrointestinal bleeding for the individual patient. Basic Clin Pharmacol Toxicol 126 (2020), 437–443.
Palareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. J Thromb Haemost 16 (2018), 1994–2002.
Badescu, M.C., Ciocoiu, M., Badulescu, O.V., Vladeanu, M.C., Bojan, I.B., Vlad, C.E., et al. Prediction of bleeding events using the VTE-BLEED risk score in patients with venous thromboembolism receiving anticoagulant therapy (Review). Exp Ther Med, 22, 2021, 1344.
Ruíz-Giménez, N., Suárez, C., González, R., Nieto, J.A., Todolí, J.A., Samperiz, A.L., et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100 (2008), 26–31.
Depietri, L., Marietta, M., Scarlini, S., Marcacci, M., Corradini, E., Pietrangelo, A., et al. Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a “real life” prospective and retrospective observational study on patients hospitalized in a Single Internal Medicine Unit (the STIME study). Intern Emerg Med 13 (2018), 527–534.
Nurden, A.T., Nurden, P., Sanchez, M., Andia, I., Anitua, E., Platelets and wound healing. Front Biosci 13 (2008), 3532–3548.
Michelson, A.D., Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9 (2010), 154–169.
Mahmoud, A.N., Elgendy, A.Y., Rambarat, C., Mahtta, D., Elgendy, I.Y., Bavry, A.A., Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. PLoS One, 12, 2017, e0175283.
Adelborg, K., Sundbøll, J., Sørensen, H.T., Arterial cardiovascular events and mortality following venous thromboembolism. Ann Transl Med, 3, 2015, 117.
Hess, C.N., Hiatt, W.R., Antithrombotic Therapy for Peripheral Artery Disease in 2018. Jama 319 (2018), 2329–2330.
Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001), 1809–1817.
Warner, T.D., Nylander, S., Whatling, C., Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 72 (2011), 619–633.
Gachet, C., P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99 (2008), 466–472.
Gurbel, P.A., Tantry, U.S., An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 305 (2011), 1136–1137.
Wallentin, L., James, S., Storey, R.F., Armstrong, M., Barratt, B.J., Horrow, J., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376 (2010), 1320–1328.
Ueno, M., Ferreiro, J.L., Angiolillo, D.J., Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 8 (2010), 1069–1077.
Hirsh, J., Warkentin, T.E., Shaughnessy, S.G., Anand, S.S., Halperin, J.L., Raschke, R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001), 64s–94s.
Pernerstorfer, T., Jilma, B., Eichler, H.G., Aull, S., Handler, S., Speiser, W., Heparin lowers plasma levels of activated factor VII. Br J Haematol 105 (1999), 1127–1129.
Heuts, L.M., Arvik, B.M., Cender, D.E., LMWH for perioperative anticoagulation in patients on chronic warfarin therapy. Ann Pharmacother 38 (2004), 1065–1069.
Bara, L., Samama, M., Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 543 (1988), 65–72.
Van Matre, E.T., Reynolds, P.M., MacLaren, R., Mueller, S.W., Wright, G.C., Moss, M., et al. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost 16 (2018), 2492–2500.
Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M., Weitz, J.I., Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 141s–159s.
Kumar, A., Talwar, A., Farley, J.F., Muzumdar, J., Schommer, J.C., Balkrishnan, R., et al. Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis. J Am Heart Assoc, 8, 2019, e012184.
Krauel, K., Fürll, B., Warkentin, T.E., Weitschies, W., Kohlmann, T., Sheppard, J.I., et al. Heparin-induced thrombocytopenia–therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 6 (2008), 2160–2167.
Magnani, H.N., Gallus, A., Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95 (2006), 967–981.
Holford, N.H., Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 11 (1986), 483–504.
Wells, P.S., Holbrook, A.M., Crowther, N.R., Hirsh, J., Interactions of warfarin with drugs and food. Ann Intern Med 121 (1994), 676–683.
Greenblatt, D.J., von Moltke, L.L., Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45 (2005), 127–132.
Walenga, J.M., Adiguzel, C., Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64 (2010), 956–967.
Kondo, L.M., Wittkowsky, A.K., Wiggins, B.S., Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 35 (2001), 440–451.
Reed, M.D., Bell, D., Clinical pharmacology of bivalirudin. Pharmacotherapy 22 (2002), 105s–111s.
Valgimigli, M., Frigoli, E., Leonardi, S., Rothenbühler, M., Gagnor, A., Calabrò, P., et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 373 (2015), 997–1009.
Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
Kakkos, S.K., Kirkilesis, G.I., Tsolakis, I.A., Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48 (2014), 565–575.
Makam, R.C.P., Hoaglin, D.C., McManus, D.D., Wang, V., Gore, J.M., Spencer, F.A., et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS One, 13, 2018, e0197583.
Momin, J.H., Candidate, P., Hughes, G.J., Andexanet Alfa (Andexxa(®)) for the Reversal of Direct Oral Anticoagulants. P t 44 (2019), 530–549.
Odén, A., Fahlén, M., Oral anticoagulation and risk of death: a medical record linkage study. Bmj 325 (2002), 1073–1075.
Kasivisvanathan, R., Abbassi-Ghadi, N., Kumar, S., Mackenzie, H., Thompson, K., James, K., et al. Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery. Br J Surg 101 (2014), 1383–1390.
Mahla, E., Metzler, H., Bornemann-Cimenti, H., Prueller, F., Raggam, R.B., Pregartner, G., et al. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study. Thromb Haemost 118 (2018), 864–872.
Dehne, S., Heck, C., Sander, J., Meisenbacher, K., Arens, C., Niklas, C., et al. Association Between Peri-OPerative Aspirin ResisTance and CardioVascular Outcome (POPART-CVO): a Prospective Non-Interventional Cohort Study. Eur J Vasc Endovasc Surg, 2022.
Siller-Matula, J.M., Petre, A., Delle-Karth, G., Huber, K., Ay, C., Lordkipanidzé, M., et al. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 6 (2017), 753–770.
Wisman, P.P., Roest, M., Asselbergs, F.W., de Groot, P.G., Moll, F.L., van der Graaf, Y., et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 12 (2014), 736–747.
Galli, M., Benenati, S., Capodanno, D., Franchi, F., Rollini, F., D'Amario, D., et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 397 (2021), 1470–1483.
Smythe, M.A., Priziola, J., Dobesh, P.P., Wirth, D., Cuker, A., Wittkowsky, A.K., Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 41 (2016), 165–186.
Smythe, M.A., Koerber, J.M., Nowak, S.N., Mattson, J.C., Begle, R.L., Westley, S.J., et al. Correlation between activated clotting time and activated partial thromboplastin times. Ann Pharmacother 36 (2002), 7–11.
Doganer, O., Wiersema, A.M., Scholtes, V., Blankensteijn, J.D., Yeung, K.K., Jongkind, V., No Concluding Evidence on Optimal Activated Clotting Time for Non-cardiac Arterial Procedures. Eur J Vasc Endovasc Surg 59 (2020), 137–147.
Wu, T., Xia, X., Chen, W., Fu, J., Zhang, J., The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis. J Clin Pharm Ther 45 (2020), 602–608.
Lip, G.Y.H., Keshishian, A., Li, X., Hamilton, M., Masseria, C., Gupta, K., et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 49 (2018), 2933–2944.
Bosch, J., Eikelboom, J.W., Connolly, S.J., Bruns, N.C., Lanius, V., Yuan, F., et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol 33 (2017), 1027–1035.
Fowkes, F.G., Price, J.F., Stewart, M.C., Butcher, I., Leng, G.C., Pell, A.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. Jama 303 (2010), 841–848.
Giannopoulos, A., Kakkos, S., Abbott, A., Naylor, A.R., Richards, T., Mikhailidis, D.P., et al. Long-term Mortality in Patients with Asymptomatic Carotid Stenosis: Implications for Statin Therapy. Eur J Vasc Endovasc Surg 50 (2015), 573–582.
Côté, R., Battista, R.N., Abrahamowicz, M., Langlois, Y., Bourque, F., Mackey, A., Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 123 (1995), 649–655.
King, A., Shipley, M., Markus, H., The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke 44 (2013), 542–546.
Marquardt, L., Geraghty, O.C., Mehta, Z., Rothwell, P.M., Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 41 (2010), e11–e17.
Murphy, S.J.X., Naylor, A.R., Ricco, J.B., Sillesen, H., Kakkos, S., Halliday, A., et al. Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. Eur J Vasc Endovasc Surg 57 (2019), 199–211.
Johnston, S.C., Rothwell, P.M., Nguyen-Huynh, M.N., Giles, M.F., Elkins, J.S., Bernstein, A.L., et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369 (2007), 283–292.
Kerr, D.M., Fulton, R.L., Lees, K.R., Seven-day NIHSS is a sensitive outcome measure for exploratory clinical trials in acute stroke: evidence from the Virtual International Stroke Trials Archive. Stroke 43 (2012), 1401–1403.
Rothwell, P.M., Algra, A., Chen, Z., Diener, H.C., Norrving, B., Mehta, Z., Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388 (2016), 365–375.
Dengler, R., Diener, H.C., Schwartz, A., Grond, M., Schumacher, H., Machnig, T., et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9 (2010), 159–166.
Sacco, R.L., Diener, H.C., Yusuf, S., Cotton, D., Ounpuu, S., Lawton, W.A., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008), 1238–1251.
Pan, Y., Elm, J.J., Li, H., Easton, J.D., Wang, Y., Farrant, M., et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol 76 (2019), 1466–1473.
King, A., Markus, H.S., Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis. Stroke 40 (2009), 3711–3717.
Batchelder, A., Hunter, J., Cairns, V., Sandford, R., Munshi, A., Naylor, A.R., Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications. Eur J Vasc Endovasc Surg 50 (2015), 412–419.
Naylor, A.R., Sayers, R.D., McCarthy, M.J., Bown, M.J., Nasim, A., Dennis, M.J., et al. Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. Eur J Vasc Endovasc Surg 46 (2013), 161–170.
Payne, D.A., Jones, C.I., Hayes, P.D., Thompson, M.M., London, N.J., Bell, P.R., et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 109 (2004), 1476–1481.
Amarenco, P., Denison, H., Evans, S.R., Himmelmann, A., James, S., Knutsson, M., et al. Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. JAMA Neurol 78 (2020), 1–9.
Stone, D.H., Goodney, P.P., Schanzer, A., Nolan, B.W., Adams, J.E., Powell, R.J., et al. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg 54 (2011), 779–784.
Kretschmer, G., Pratschner, T., Prager, M., Wenzl, E., Polterauer, P., Schemper, M., et al. Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial. Ann Surg 211 (1990), 317–322.
Lindblad, B., Persson, N.H., Takolander, R., Bergqvist, D., Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 24 (1993), 1125–1128.
Donners, S.J.A., Mekke, J.M., van Hattum, E.S., Toorop, R.J., de Borst, G.J., Editor's Choice - Risk of Bleeding Complications With Different Peri-Operative Antithrombotic Regimens During Carotid Endarterectomy: a National Registry Analysis. Eur J Vasc Endovasc Surg 64 (2022), 444–451.
Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351 (1998), 1379–1387.
Ferguson, G.G., Eliasziw, M., Barr, H.W., Clagett, G.P., Barnes, R.W., Wallace, M.C., et al. The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients. Stroke 30 (1999), 1751–1758.
de Vries, E.E., Vonken, E.J., Kappelle, L.J., Toorop, R.J., de Borst, G.J., Short-Term Double Layer Mesh Stent Patency for Emergent or Elective Carotid Artery Stenting. Stroke 50 (2019), 1898–1901.
Huibers, A.E., Westerink, J., de Vries, E.E., Hoskam, A., den Ruijter, H.M., Moll, F.L., et al. Editor's Choice - Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg 56 (2018), 322–333.
McKevitt, F.M., Randall, M.S., Cleveland, T.J., Gaines, P.A., Tan, K.T., Venables, G.S., The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 29 (2005), 522–527.
Dalainas, I., Nano, G., Bianchi, P., Stegher, S., Malacrida, G., Tealdi, D.G., Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol 29 (2006), 519–521.
Bates, E.R., Babb, J.D., Casey, D.E., Cates, C.U., Duckwiler, G.R., Feldman, T.E., et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting). J Am Coll Cardiol 49 (2007), 126–170.
Navarese, E.P., Andreotti, F., Schulze, V., Kołodziejczak, M., Buffon, A., Brouwer, M., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. Bmj, 350, 2015, h1618.
Diener, H.C., Bogousslavsky, J., Brass, L.M., Cimminiello, C., Csiba, L., Kaste, M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004), 331–337.
Anand, S.S., Caron, F., Eikelboom, J.W., Bosch, J., Dyal, L., Aboyans, V., et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol 71 (2018), 2306–2315.
Aboyans, V., Criqui, M.H., McDermott, M.M., Allison, M.A., Denenberg, J.O., Shadman, R., et al. The vital prognosis of subclavian stenosis. J Am Coll Cardiol 49 (2007), 1540–1545.
Labropoulos, N., Nandivada, P., Bekelis, K., Prevalence and impact of the subclavian steal syndrome. Ann Surg 252 (2010), 166–170.
Shadman, R., Criqui, M.H., Bundens, W.P., Fronek, A., Denenberg, J.O., Gamst, A.C., et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol 44 (2004), 618–623.
Schillinger, M., Haumer, M., Schillinger, S., Mlekusch, W., Ahmadi, R., Minar, E., Outcome of conservative versus interventional treatment of subclavian artery stenosis. J Endovasc Ther 9 (2002), 139–146.
Sana, A., van Noord, D., Mensink, P.B., Kooij, S., van Dijk, K., Bravenboer, B., et al. Patients with chronic gastrointestinal ischemia have a higher cardiovascular disease risk and mortality. Atherosclerosis 224 (2012), 235–241.
Raman, G., Adam, G.P., Halladay, C.W., Langberg, V.N., Azodo, I.A., Balk, E.M., Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review. Ann Intern Med 165 (2016), 635–649.
Ritchie, J., Green, D., Alderson, H.V., Chrysochou, C., Vassallo, D., Sinha, S., et al. Associations of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic renovascular disease. J Am Soc Hypertens 10 (2016), 149–158.e3.
Oderich, G.S., Tallarita, T., Gloviczki, P., Duncan, A.A., Kalra, M., Misra, S., et al. Mesenteric artery complications during angioplasty and stent placement for atherosclerotic chronic mesenteric ischemia. J Vasc Surg 55 (2012), 1063–1071.
Acosta-Mérida, M.A., Marchena-Gómez, J., Saavedra-Santana, P., Silvestre-Rodríguez, J., Artiles-Armas, M., Callejón-Cara, M.M., Surgical Outcomes in Acute Mesenteric Ischemia: Has Anything Changed Over the Years?. World J Surg 44 (2020), 100–107.
Song, P., Rudan, D., Zhu, Y., Fowkes, F.J.I., Rahimi, K., Fowkes, F.G.R., et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7 (2019), e1020–e1030.
Bhatt, D.L., Eagle, K.A., Ohman, E.M., Hirsch, A.T., Goto, S., Mahoney, E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. Jama 304 (2010), 1350–1357.
Hess, C.N., Norgren, L., Ansel, G.M., Capell, W.H., Fletcher, J.P., Fowkes, F.G.R., et al. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation 135 (2017), 2534–2555.
McClure, G.R., Kaplovitch, E., Narula, S., Bhagirath, V.C., Anand, S.S., Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. Curr Cardiol Rep, 21, 2019, 115.
Savarese, G., Reiner, M.F., Uijl, A., D'Amario, D., Agewall, S., Atar, D., et al. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Pharmacother 6 (2020), 86–93.
Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
Robless, P., Mikhailidis, D.P., Stansby, G., Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 88 (2001), 787–800.
Peters, F., Kreutzburg, T., Rieß, H.C., Heidemann, F., Marschall, U., L'Hoest, H., et al. Editor's Choice - Optimal Pharmacological Treatment of Symptomatic Peripheral Arterial Occlusive Disease and Evidence of Female Patient Disadvantage: An Analysis of Health Insurance Claims Data. Eur J Vasc Endovasc Surg 60 (2020), 421–429.
Sigvant, B., Kragsterman, B., Falkenberg, M., Hasvold, P., Johansson, S., Thuresson, M., et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg 64 (2016), 1009–1017.e3.
Sigvant, B., Hasvold, P., Kragsterman, B., Falkenberg, M., Johansson, S., Thuresson, M., et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. J Vasc Surg 66 (2017), 507–514.e1.
Nastasi, D.R., Smith, J.R., Moxon, J.V., Trollope, A., Golledge, J., Prescription of Pharmacotherapy and the Incidence of Stroke in Patients With Symptoms of Peripheral Artery Disease. Stroke 49 (2018), 2953–2960.
Berger, J.S., Krantz, M.J., Kittelson, J.M., Hiatt, W.R., Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. Jama 301 (2009), 1909–1919.
Qian, J., Yang, X.H., A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease. Medicine (Baltimore), 94, 2015, e1293.
van Geffen, J.P., Kleinegris, M.C., Verdoold, R., Baaten, C.C., Cosemans, J.M., Clemetson, K.J., et al. Normal platelet activation profile in patients with peripheral arterial disease on aspirin. Thromb Res 135 (2015), 513–520.
Brown, T., Forster, R.B., Cleanthis, M., Mikhailidis, D.P., Stansby, G., Stewart, M., Cilostazol for intermittent claudication. Cochrane Database Syst Rev, 6, 2021, Cd003748.
European Medicines Agency, Cilostazol-containing medicines. 2013. https://www.ema.europa.eu/en/medicines/human/referrals/cilostazol-containing-medicines, 2013.
Bonaca, M.P., Scirica, B.M., Creager, M.A., Olin, J., Bounameaux, H., Dellborg, M., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2P-TIMI 50. Circulation 127 (2013), 1522–1529.
Bhatt, D.L., Flather, M.D., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007), 1982–1988.
Cacoub, P.P., Bhatt, D.L., Steg, P.G., Topol, E.J., Creager, M.A., Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30 (2009), 192–201.
Fanari, Z., Malodiya, A., Weiss, S.A., Hammami, S., Kolm, P., Weintraub, W.S., Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 18 (2017), 10–15.
De Schryver, E.L., Algra, A., van Gijn, J., Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev, 2007, Cd001820.
De Carlo, M., Di Minno, G., Sayre, T., Fazeli, M.S., Siliman, G., Cimminiello, C., Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Curr Vasc Pharmacol 19 (2021), 542–555.
Geeganage, C., Wilcox, R., Bath, P.M., Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med, 8, 2010, 36.
Cosmi, B., Conti, E., Coccheri, S., Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev, 5, 2014, CD001999.
Eikelboom, J.W., Connolly, S.J., Bosch, J., Dagenais, G.R., Hart, R.G., Shestakovska, O., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 377 (2017), 1319–1330.
Kaplovitch, E., Eikelboom, J.W., Dyal, L., Aboyans, V., Abola, M.T., Verhamme, P., et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiol 6 (2021), 21–29.
Ambler, G.K., Nordanstig, J., Behrendt, C.A., Twine, C.P., Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. Eur J Vasc Endovasc Surg 62 (2021), 654–655.
Kreutzburg, T., Peters, F., Kuchenbecker, J., Marschall, U., Lee, R., Kriston, L., et al. Editor's Choice - The GermanVasc Score: A Pragmatic Risk Score Predicts Five Year Amputation Free Survival in Patients with Peripheral Arterial Occlusive Disease. Eur J Vasc Endovasc Surg 61 (2021), 248–256.
Nickinson, A.T.O., Coles, B., Zaccardi, F., Gray, L.J., Payne, T., Bown, M.J., et al. Missed Opportunities for Timely Recognition of Chronic Limb Threatening Ischaemia in Patients Undergoing a Major Amputation: A Population Based Cohort Study Using the UK's Clinical Practice Research Datalink. Eur J Vasc Endovasc Surg 60 (2020), 703–710.
Baubeta Fridh, E., Andersson, M., Thuresson, M., Sigvant, B., Kragsterman, B., Johansson, S., et al. Editor's Choice - Impact of Comorbidity, Medication, and Gender on Amputation Rate Following Revascularisation for Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg 56 (2018), 681–688.
Long, C.A., Mulder, H., Fowkes, F.G.R., Baumgartner, I., Berger, J.S., Katona, B.G., et al. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circ Cardiovasc Qual Outcomes, 13, 2020, e006399.
Norgren, L., Patel, M.R., Hiatt, W.R., Wojdyla, D.M., Fowkes, F.G.R., Baumgartner, I., et al. Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. Eur J Vasc Endovasc Surg 55 (2018), 109–117.
Baumgartner, I., Norgren, L., Fowkes, F.G.R., Mulder, H., Patel, M.R., Berger, J.S., et al. Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. J Am Coll Cardiol 72 (2018), 1563–1572.
Bjorck, M., Earnshaw, J.J., Acosta, S., Bastos Goncalves, F., Cochennec, F., Debus, E.S., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg 59 (2020), 173–218.
Jongkind, V., Earnshaw, J.J., Bastos Goncalves, F., Cochennec, F., Debus, E.S., Hinchliffe, R., et al. Editor's Choice - Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Review of the Literature. Eur J Vasc Endovasc Surg 63 (2022), 80–89.
Creager, M.A., Kaufman, J.A., Conte, M.S., Clinical practice. Acute limb ischemia. N Engl J Med 366 (2012), 2198–2206.
Hess, C.N., Huang, Z., Patel, M.R., Baumgartner, I., Berger, J.S., Blomster, J.I., et al. Acute Limb Ischemia in Peripheral Artery Disease. Circulation 140 (2019), 556–565.
Thompson, J.F., Mullee, M.A., Bell, P.R., Campbell, W.B., Chant, A.D., Darke, S.G., et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg 12 (1996), 86–90.
Duschek, N., Vafaie, M., Skrinjar, E., Hirsch, K., Waldhör, T., Hübl, W., et al. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. J Thromb Haemost 9 (2011), 2159–2167.
Verheugt, F.W., Steinhubl, S.R., Hamon, M., Darius, H., Steg, P.G., Valgimigli, M., et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv 4 (2011), 191–197.
Hu, Y., Liu, A.Y., Zhang, L., Wu, X., Shi, S., Elmore, J.R., et al. A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures. J Vasc Surg 70 (2019), 274–284.e5.
Qureshi, M.I., Li, H.L., Ambler, G.K., Wong, K.H.F., Dawson, S., Chaplin, K., et al. Antiplatelet and Anticoagulant Use in Randomised Trials of Patients Undergoing Endovascular Intervention for Peripheral Arterial Disease: Systematic Review and Narrative Synthesis. Eur J Vasc Endovasc Surg 60 (2020), 77–87.
Wong, K.H.F., Bosanquet, D.C., Ambler, G.K., Qureshi, M.I., Hinchliffe, R.J., Twine, C.P., The CLEAR (Considering Leading Experts' Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention. CVIR Endovasc, 2, 2019, 37.
Katsanos, K., Spiliopoulos, S., Saha, P., Diamantopoulos, A., Karunanithy, N., Krokidis, M., et al. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. PLoS One, 10, 2015, e0135692.
Megaly, M., Abraham, B., Saad, M., Mekaiel, A., Soukas, P., Banerjee, S., et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med 24 (2019), 313–323.
Hiatt, W.R., Bonaca, M.P., Patel, M.R., Nehler, M.R., Debus, E.S., Anand, S.S., et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation 142 (2020), 2219–2230.
Moll, F., Baumgartner, I., Jaff, M., Nwachuku, C., Tangelder, M., Ansel, G., et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. J Endovasc Ther 25 (2018), 158–168.
Bauersachs, R., Wu, O., Hawkins, N., Bowrin, K., Wojciechowski, P., Clay, E., et al. Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis. Cardiovasc Ther, 2021, 2021, 8561350.
Bedenis, R., Lethaby, A., Maxwell, H., Acosta, S., Prins, M.H., Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev, 2015, 2015, Cd000535.
van Hattum, E.S., Algra, A., Lawson, J.A., Eikelboom, B.C., Moll, F.L., Tangelder, M.J., Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation 120 (2009), 1569–1576.
Johnson, W.C., Williford, W.O., Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 35 (2002), 413–421.
Monaco, M., Di Tommaso, L., Pinna, G.B., Lillo, S., Schiavone, V., Stassano, P., Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. J Vasc Surg 56 (2012), 96–105.
de Smit, P., van Ark, H., Dutch oral anticoagulation trial. Acta Chirurgica Austriaca 24 (1992), 5–7.
Debus, E.S., Nehler, M.R., Govsyeyev, N., Bauersachs, R.M., Anand, S.S., Patel, M.R., et al. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation 144 (2021), 1104–1116.
Aksu, K., Donmez, A., Keser, G., Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 18 (2012), 1478–1493.
Emmi, G., Bettiol, A., Silvestri, E., Di Scala, G., Becatti, M., Fiorillo, C., et al. Vascular Behçet's syndrome: an update. Intern Emerg Med 14 (2019), 645–652.
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79 (2020), 19–30.
Ferfar, Y., Savey, L., Comarmond, C., Sadaghianloo, N., Garrido, M., Domont, F., et al. Large-vessel vasculitis in human immunodeficiency virus-infected patients. J Vasc Surg 67 (2018), 1501–1511.
Vega, L.E., Espinoza, L.R., Vasculitides in HIV Infection. Curr Rheumatol Rep, 22, 2020, 60.
Sadeghipour, P., Talasaz, A.H., Rashidi, F., Sharif-Kashani, B., Beigmohammadi, M.T., Farrokhpour, M., et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. Jama 325 (2021), 1620–1630.
Baccellieri, D., Bilman, V., Apruzzi, L., Monaco, F., D'Angelo, A., Loschi, D., et al. A Case of Covid-19 Patient with Acute Limb Ischemia and Heparin Resistance. Ann Vasc Surg 68 (2020), 88–92.
Beun, R., Kusadasi, N., Sikma, M., Westerink, J., Huisman, A., Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 42:Suppl 1 (2020), 19–20.
White, D., MacDonald, S., Bull, T., Hayman, M., de Monteverde-Robb, R., Sapsford, D., et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 50 (2020), 287–291.
Campbell, W.B., Ridler, B.M., Szymanska, T.H., Two-year follow-up after acute thromboembolic limb ischaemia: the importance of anticoagulation. Eur J Vasc Endovasc Surg 19 (2000), 169–173.
Forbes, T.L., DeRose, G., Harris, K.A., Is long-term anticoagulation after acute thromboembolic limb ischemia always necessary?. Can J Surg 45 (2002), 337–340.
Diener, H.C., Sacco, R.L., Easton, J.D., Granger, C.B., Bernstein, R.A., Uchiyama, S., et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med 380 (2019), 1906–1917.
Healey, J.S., Gladstone, D.J., Swaminathan, B., Eckstein, J., Mundl, H., Epstein, A.E., et al. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol 76 (2019), 764–773.
Geisler, T., Poli, S., Meisner, C., Schreieck, J., Zuern, C.S., Nägele, T., et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 12 (2017), 985–990.
Bath, M.F., Gokani, V.J., Sidloff, D.A., Jones, L.R., Choke, E., Sayers, R.D., et al. Systematic review of cardiovascular disease and cardiovascular death in patients with a small abdominal aortic aneurysm. Br J Surg 102 (2015), 866–872.
Bahia, S.S., Vidal-Diez, A., Seshasai, S.R., Shpitser, I., Brownrigg, J.R., Patterson, B.O., et al. Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. Br J Surg 103 (2016), 1626–1633.
Lindholt, J.S., Sorensen, H.T., Michel, J.B., Thomsen, H.F., Henneberg, E.W., Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 42 (2008), 329–334.
Wanhainen, A., Mani, K., Kullberg, J., Svensjö, S., Bersztel, A., Karlsson, L., et al. The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial. Cardiovasc Res 116 (2020), 450–456.
Biccard, B.M., Sigamani, A., Chan, M.T.V., Sessler, D.I., Kurz, A., Tittley, J.G., et al. Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2). Br J Surg 105 (2018), 1591–1597.
Grant, S.W., Grayson, A.D., Purkayastha, D., Wilson, S.D., McCollum C and participants in the Vascular Governance North West P. Logistic risk model for mortality following elective abdominal aortic aneurysm repair. Br J Surg 98 (2011), 652–658.
Eldrup, N., Budtz-Lilly, J., Laustsen, J., Bibby, B.M., Paaske, W.P., Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms. J Vasc Surg 55 (2012), 311–317.
Dzieciuchowicz, Ł., Łukaszuk, M., Figiel, J., Klimczak, K., Krasiński, Z., Majewski, W., Factors influencing the clinical course of popliteal artery aneurysm. Med Sci Monit 15 (2009), Cr231–r235.
Tielliu, I.F., Verhoeven, E.L., Zeebregts, C.J., Prins, T.R., Span, M.M., van den Dungen, J.J., Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study. J Vasc Surg 41 (2005), 561–567.
Stiegler, H., Mendler, Baumann, A., Prospektiver Verlauf von 36 Patienten mit 46 Poplitealaneurysmata unter konservativer Therapie. Vasa 1 (2002), 43–46.
Shah, N.G., Rokosh, R.S., Garg, K., Safran, B., Rockman, C.B., Maldonado, T.S., et al. Endovascular treatment of popliteal artery aneurysms has comparable long-term outcomes to open repair with shorter lengths of stay. J Vasc Surg 74 (2021), 1565–1572.e1.
Chemtob, R.A., Moeller-Soerensen, H., Holmvang, L., Olsen, P.S., Ravn, H.B., Outcome After Surgery for Acute Aortic Dissection: Influence of Preoperative Antiplatelet Therapy on Prognosis. J Cardiothorac Vasc Anesth 31 (2017), 569–574.
Hansson, E.C., Dellborg, M., Lepore, V., Jeppsson, A., Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality. Heart 99 (2013), 116–121.
He, R.X., Zhang, L., Zhou, T.N., Yuan, W.J., Liu, Y.J., Fu, W.X., et al. Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. Chin Med J (Engl) 130 (2017), 2321–2325.
Chowdhury, M.M., Sabbagh, C.N., Jackson, D., Coughlin, P.A., Ghosh, J., Antithrombotic treatment for acute extracranial carotid artery dissections: a meta-analysis. Eur J Vasc Endovasc Surg 50 (2015), 148–156.
Engelter, S.T., Traenka, C., Gensicke, H., Schaedelin, S.A., Luft, A.R., Simonetti, B.G., et al. Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial. Lancet Neurol 20 (2021), 341–350.
Ahn, S., Mo, H., Han, A., Min, S.I., Min, S.K., Ha, J., et al. The Use of Antithrombotics Is Not Beneficial for Conservative Management of Spontaneous Isolated Dissection of the Superior Mesenteric Artery: A Meta-analysis. Ann Vasc Surg 60 (2019), 415–423.e4.
Smith, G.E., Souroullos, P., Cayton, T., Harwood, A., Carradice, D., Chetter, I.C., A systematic review and meta-analysis of systemic intraoperative anticoagulation during arteriovenous access formation for dialysis. J Vasc Access 17 (2016), 1–5.
Palmer, S.C., Di Micco, L., Razavian, M., Craig, J.C., Ravani, P., Perkovic, V., et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis 61 (2013), 112–122.
Dember, L.M., Beck, G.J., Allon, M., Delmez, J.A., Dixon, B.S., Greenberg, A., et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. Jama 299 (2008), 2164–2171.
Hsu, Y.H., Yen, Y.C., Lin, Y.C., Sung, L.C., Antiplatelet agents maintain arteriovenous fistula and graft function in patients receiving hemodialysis: A nationwide case-control study. PLoS One, 13, 2018, e0206011.
Foley, R.N., Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care 36:Suppl 1 (2010), 4–8.
Said, S., Hernandez, G.T., The link between chronic kidney disease and cardiovascular disease. J Nephropathol 3 (2014), 99–104.
Wattanakit, K., Cushman, M., Stehman-Breen, C., Heckbert, S.R., Folsom, A.R., Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19 (2008), 135–140.
Ding, W.Y., Gupta, D., Wong, C.F., Lip, G.Y.H., Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res 117 (2021), 1046–1059.
Kaw, D., Malhotra, D., Platelet dysfunction and end-stage renal disease. Semin Dial 19 (2006), 317–322.
Moal, V., Brunet, P., Dou, L., Morange, S., Sampol, J., Berland, Y., Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 18 (2003), 1834–1841.
Nunns, G.R., Moore, E.E., Chapman, M.P., Moore, H.B., Stettler, G.R., Peltz, E., et al. The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. Am J Surg 214 (2017), 1215–1218.
Darlington, A., Ferreiro, J.L., Ueno, M., Suzuki, Y., Desai, B., Capranzano, P., et al. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 106 (2011), 67–74.
Major, R.W., Oozeerally, I., Dawson, S., Riddleston, H., Gray, L.J., Brunskill, N.J., Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis 251 (2016), 177–182.
Best, P.J., Steinhubl, S.R., Berger, P.B., Dasgupta, A., Brennan, D.M., Szczech, L.A., et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155 (2008), 687–693.
Fox, K.A.A., Eikelboom, J.W., Shestakovska, O., Connolly, S.J., Metsarinne, K.P., Yusuf, S., Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol 73 (2019), 2243–2250.
Feldberg, J., Patel, P., Farrell, A., Sivarajahkumar, S., Cameron, K., Ma, J., et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant 34 (2019), 265–277.
Alhousani, M., Malik, S.U., Abu-Hashyeh, A., Poznanski, N.J., Al-Hasan, S., Roth, D.F., et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb Res 198 (2021), 103–114.
Lim, W., Dentali, F., Eikelboom, J.W., Crowther, M.A., Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006), 673–684.
Hoffmann, P., Keller, F., Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 68 (2012), 757–765.
Navi, B.B., Reiner, A.S., Kamel, H., Iadecola, C., Okin, P.M., Elkind, M.S.V., et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol 70 (2017), 926–938.
Navi, B.B., Reiner, A.S., Kamel, H., Iadecola, C., Okin, P.M., Tagawa, S.T., et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 133 (2019), 781–789.
Alberts, M.J., Bhatt, D.L., Mas, J.L., Ohman, E.M., Hirsch, A.T., Röther, J., et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 30 (2009), 2318–2326.
Winkel, T.A., Hoeks, S.E., Schouten, O., Zeymer, U., Limbourg, T., Baumgartner, I., et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg 40 (2010), 9–16.
Valgimigli, M., Bueno, H., Byrne, R.A., Collet, J.P., Costa, F., Jeppsson, A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39 (2018), 213–260.
Sarac, T.P., Huber, T.S., Back, M.R., Ozaki, C.K., Carlton, L.M., Flynn, T.C., et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 28 (1998), 446–457.
Wave, Investigators, The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J 151 (2006), 1–9.
Gurbel, P.A., Fox, K.A.A., Tantry, U.S., Ten Cate, H., Weitz, J.I., Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation 139 (2019), 2170–2185.
May, J.E., Moll, S., How I treat unexplained arterial thrombosis. Blood 136 (2020), 1487–1498.
Kim, R.J., Becker, R.C., Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146 (2003), 948–957.
Ye, Z., Liu, E.H., Higgins, J.P., Keavney, B.D., Lowe, G.D., Collins, R., et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367 (2006), 651–658.
Mannucci, P.M., Asselta, R., Duga, S., Guella, I., Spreafico, M., Lotta, L., et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost 8 (2010), 2116–2121.
Chiasakul, T., De Jesus, E., Tong, J., Chen, Y., Crowther, M., Garcia, D., et al. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 8, 2019, e012877.
Vazquez, F., Rodger, M., Carrier, M., Le Gal, G., Reny, J.L., Sofi, F., et al. Prothrombin G20210A mutation and lower extremity peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 50 (2015), 232–240.
Mahmoodi, B.K., Brouwer, J.L., Veeger, N.J., van der Meer, J., Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 118 (2008), 1659–1667.
Neville, C., Rauch, J., Kassis, J., Chang, E.R., Joseph, L., Le Comte, M., et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 90 (2003), 108–115.
Zakai, N.A., Judd, S.E., Kissela, B., Howard, G., Safford, M.M., Cushman, M., Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS). Thromb Haemost 118 (2018), 1305–1315.
Folsom, A.R., Delaney, J.A., Lutsey, P.L., Zakai, N.A., Jenny, N.S., Polak, J.F., et al. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 84 (2009), 349–353.
Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama 288 (2002), 2015–2022.
Klerk, M., Verhoef, P., Clarke, R., Blom, H.J., Kok, F.J., Schouten, E.G., MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. Jama 288 (2002), 2023–2031.
Baglin, T., Gray, E., Greaves, M., Hunt, B.J., Keeling, D., Machin, S., et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149 (2010), 209–220.
Stevens, P.E., Levin, A., Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158 (2013), 825–830.
Bala, M.M., Celinska-Lowenhoff, M., Szot, W., Padjas, A., Kaczmarczyk, M., Swierz, M.J., et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev, 10, 2020, Cd012169.
Toth, S., Flohr, T.R., Schubart, J., Knehans, A., Castello, M.C., Aziz, F., A meta-analysis and systematic review of venous thromboembolism prophylaxis in patients undergoing vascular surgery procedures. J Vasc Surg Venous Lymphat Disord 8 (2020), 869–881.e2.
Nicolaides, A.N., Fareed, J., Kakkar, A.K., Comerota, A.J., Goldhaber, S.Z., Hull, R., et al. Prevention and treatment of venous thromboembolism–International Consensus Statement. Int Angiol 32 (2013), 111–260.
Andras, A., Sala Tenna, A., Stewart, M., Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev, 7, 2017, Cd002001.
Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
Raskob, G.E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 378 (2018), 615–624.
Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
Cohen, A.T., Hamilton, M., Mitchell, S.A., Phatak, H., Liu, X., Bird, A., et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One, 10, 2015, e0144856.
Wu, X., Cao, S., Yu, B., He, T., Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 33 (2022), 389–401.
Gullapalli, K., Prasad, R.M., Al-Abcha, A., Hussain, Z., Alsouqi, A., Mosalem, O., et al. Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. Cureus, 14, 2022, e29449.
Marik, P.E., Cavallazzi, R., Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLoS One, 10, 2015, e0143252.
Vasanthamohan, L., Boonyawat, K., Chai-Adisaksopha, C., Crowther, M., Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16 (2018), 1288–1295.
Blin, P., Sevestre, M.A., Pouchain, D., Gillet, J.L., Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study. Thromb Res 157 (2017), 117–119.
Galanaud, J.P., Blaise, S., Sevestre, M.A., Terrisse, H., Pernod, G., Gaillard, C., et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res 171 (2018), 179–186.
Nikolakopoulos, K.M., Kakkos, S.K., Papageorgopoulou, C.P., Tsolakis, I.A., Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with Tinzaparin. Vasc Specialist Int 34 (2018), 1–9.
Lozano, F.S., Almazan, A., Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg 37 (2003), 415–420.
Di Nisio, M., Wichers, I.M., Middeldorp, S., Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev, 2, 2018, Cd004982.
Duffett, L., Kearon, C., Rodger, M., Carrier, M., Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost 119 (2019), 479–489.
Bauersachs, R., Gerlach, H.E., Heinken, A., Hoffmann, U., Langer, F., Noppeney, T., et al. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg 62 (2021), 241–249.
Marchiori, A., Verlato, F., Sabbion, P., Camporese, G., Rosso, F., Mosena, L., et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica 87 (2002), 523–527.
Prandoni, P., Tormene, D., Pesavento, R., Vesalio Investigators, G., High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 3 (2005), 1152–1157.
Varki, A., Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110 (2007), 1723–1729.
Gussoni, G., Frasson, S., La Regina, M., Di Micco, P., Monreal, M., Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 131 (2013), 24–30.
Spencer, F.A., Lessard, D., Emery, C., Reed, G., Goldberg, R.J., Venous thromboembolism in the outpatient setting. Arch Intern Med 167 (2007), 1471–1475.
Blom, J.W., Doggen, C.J., Osanto, S., Rosendaal, F.R., Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama 293 (2005), 715–722.
Sørensen, H.T., Mellemkjaer, L., Olsen, J.H., Baron, J.A., Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000), 1846–1850.
Kirkilesis, G.I., Kakkos, S.K., Tsolakis, I.A., Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Eur J Vasc Endovasc Surg 57 (2019), 685–701.
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M.V., Connors, J.M., et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 382 (2020), 1599–1607.
McBane, R.D. 2nd, Wysokinski, W.E., Le-Rademacher, J.G., Zemla, T., Ashrani, A., Tafur, A., et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18 (2020), 411–421.
Young, A.M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 36 (2018), 2017–2023.
Planquette, B., Bertoletti, L., Charles-Nelson, A., Laporte, S., Grange, C., Mahé, I., et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest 161 (2021), 781–790.
Sabatino, J., De Rosa, S., Polimeni, A., Sorrentino, S., Indolfi, C., Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis. JACC CardioOncol 2 (2020), 428–440.
Wang, H., Sun, Z., Jiang, W., Zhang, Y., Li, X., Wu, Y., Postoperative prophylaxis of venous thromboembolism (VTE) in patients undergoing high ligation and stripping of the great saphenous vein (GSV). Vasc Med 20 (2015), 117–121.
Dattani, N., Shalhoub, J., Nandhra, S., Lane, T., Abu-Own, A., Elbasty, A., et al. Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study. Phlebology 35 (2020), 706–714.
Keo, H.H., Spinedi, L., Staub, D., Diehm, N., Holtz, D., Broz, P., et al. Duration of pharmacological thromboprophylaxis after outpatient endovenous laser ablation: a propensity score-matched analysis. Swiss Med Wkly, 149, 2019, w20166.
Attaran, R.R., Ozdemir, D., Lin, I.H., Mena-Hurtado, C., Lansky, A., Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. J Vasc Surg Venous Lymphat Disord 7 (2019), 527–534.
Notten, P., Ten Cate, H., Ten Cate-Hoek, A.J., Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review. J Thromb Haemost 19 (2021), 753–796.
Barbara, D.W., Wilson, J.L., Anesthesia for surgery related to Klippel-Trenaunay syndrome: a review of 136 anesthetics. Anesth Analg 113 (2011), 98–102.
Oduber, C.E., van Beers, E.J., Bresser, P., van der Horst, C.M., Meijers, J.C., Gerdes, V.E., Venous thromboembolism and prothrombotic parameters in Klippel-Trenaunay syndrome. Neth J Med 71 (2013), 246–252.
Mazoyer, E., Enjolras, O., Bisdorff, A., Perdu, J., Wassef, M., Drouet, L., Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 144 (2008), 861–867.
Dompmartin, A., Acher, A., Thibon, P., Tourbach, S., Hermans, C., Deneys, V., et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 144 (2008), 873–877.
Lee, B.B., Baumgartner, I., Berlien, P., Bianchini, G., Burrows, P., Gloviczki, P., et al. Diagnosis and Treatment of Venous Malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013. Int Angiol 34 (2015), 97–149.
Levi, M., Current understanding of disseminated intravascular coagulation. Br J Haematol 124 (2004), 567–576.
Mattassi, R., Vaghi, M., Management of the marginal vein: current issues. Phlebology 22 (2007), 283–286.
Mazoyer, E., Enjolras, O., Laurian, C., Houdart, E., Drouet, L., Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol 24 (2002), 243–251.
Vandenbriele, C., Vanassche, T., Peetermans, M., Verhamme, P., Peerlinck, K., Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation. J Thromb Thrombolysis 38 (2014), 121–123.
Yasumoto, A., Ishiura, R., Narushima, M., Yatomi, Y., Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations. Blood Coagul Fibrinolysis 28 (2017), 670–674.
Mack, J.M., Richter, G.T., Crary, S.E., Effectiveness and Safety of Treatment with Direct Oral Anticoagulant Rivaroxaban in Patients with Slow-Flow Vascular Malformations: A Case Series. Lymphat Res Biol 16 (2018), 278–281.
Nordanstig, J., James, S., Andersson, M., Andersson, M., Danielsson, P., Gillgren, P., et al. Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease. N Engl J Med 383 (2020), 2538–2546.
